Catalan company INBRAIN Neuroelectronics, a member of Catalonia.health, has announced the completion of patient enrolment in its first-in-human study of graphene-based neural interfaces for brain decoding and mapping.
The study evaluates the company’s cortical interface technology and has enrolled a total of ten patients, eight of whom have undergone surgical procedures. No device-related failures or adverse events were reported during its use.
The clinical trial aims to assess the safety of the neural interface, as well as its signal quality, stability, and capability for brain stimulation and recording in real surgical settings.
INBRAIN’s technology is based on graphene, a material that enables ultra-high-resolution neural signal acquisition and supports real-time brain activity decoding, with potential applications in the treatment of neurological disorders.
The completion of enrolment marks a significant milestone in the clinical development of this technology and its future translation into therapeutic applications, with final results expected in 2026.
Comments